The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
Foreverwaiting. To be fair to AS (and I agree we need to hear more about the fund raises), he has done a remarkable job, with the company he has been pivotal in building, and the success of the trials to date. We will probably all (except for a few non-entities on here) be lauding him before the year is out. He should be rightly proud of his achievements, and calling people like him names is a bit pathetic, whatever our concerns.
Energy - 'Has any company ever presented chemo results to the FDA with so little side effects',
I think probably not - thank you for the level-headed positivity. It's easy to become swamped with the trolls' BS, and underestimate the probability of the amazing success story we have here.
My opinion, there's a time for investments, and that would have been after any licensing deals, when you have clearer routes to cash generation. The profits Launch make may cover the interest and other associated deal/integration costs over time, but was a terrible deal for shareholders.
AVCT - have re-read the RNS's at the time of the Height's raise, and the MM notes at the time.
On reflection, MM was positive about the DX acquisition, not sure where you get your reason for talking about someone's margin call - that is making a negative assumption, and you're playing the man not the ball, unnecessary. The reason for our travails have not been all AS or Avacta's fault. From a business/ science perspective they have been remarkably successful, and who here would think that a company having a trial demonstrating early signs of efficacy and amazing safety profile, would not have this somehow reflected in their SP, and not have BP biting their hands off for a valuable license deal. The above was the case in Jan 23 RNS.
To their credit they didn't take the cheap license deals that were 'offered', thereby devaluing the trial and the product. I would still, however like to hear some reasoning for the pump fake given to shareholders, around "funding, don't worry about it" followed months later, without retraction of the above statement, by a 50p fundraise to regain confidence that AS does have some alignment with shareholders, and we are not going to be trodden underfoot for AS's ambitions for Avacta and himself. I've been invested since Feb-21, and have been happy buying more shares each month for the past two years. This month, I would like to hear AS talking to shareholders openly.
Bella,
if you don't mind me asking, how closely do you believe is AS aligned with shareholders?
He spoke yesterday about requiring a financial runway to support a strong negotiating position re; license deals, and clearly this is reasonable, but I think he needs to go one further and explain the boards' thinking around the Height's fund-raise and the DX investment case, to acknowledge mistakes, and demonstrate lessons have been learnt.
As was pointed out at the time by MM amongst others (probably yourself included), the DX acquisition was a terrible use of the companies' resources, and burdened the company with unnecessary debt, which ultimately left us in a position where we had to raise more funds at 50p.
If they cannot see or acknowledge errors, they probably won't learn, hence my question.
For info, been a SH since Feb 21, and building a stronger position every month. Not a trader, just want the company and SHs to do well.
To be fair Bein, he didn't state AVA6000 was valued at €250m. He gave an example of Immunicore(sic?) with a single commercial-stage orphan-indicator targeted drug (annual revenues of €250m) valuing that company at €3.1b.
Avacta are going it alone for orphan indicators with 6000, but are looking to partner for eg, Breast, Ovarian etc.
The results presented this week were fantastic I'm sure you agree, so the first licensing deal for the above, and it's value, unlocks the MCap of the whole company. They've rightly (IMO) not rushed into smaller deals for this very reason.
Notrex, I would control your posting, as you come across as rather rude and immature. I'm going to filter you because I have found that people like yourself take up too much room, and offer little or nothing to any constructive debate.
Perhaps you should learn to sit, read and listen, before replying.
Avacta currently recruiting: this senior #medicinalchemistry #opportunity for Avacta Therapeutics. ................. flexible role for this #immunooncology #biotech at such an exciting stage of growth. Two very exciting pipelines, inspiring collaborators and a fantastic opportunity to grow your profile and develop your expertise.
TonyFawcett: so sorry to hear about your illness. I find it incomprehensibly ignorant that they have not bothered to reply to you, at least out of courtesy; as you are exactly the sort of person that Avacta and other Pharma companies should be trying to help. If not their trial; they could assist with other trials that are ongoing.
Had an email response within hours from a US company that are undergoing later stage trials related to Parkinson's (hoping to help a a colleague).
Best of luck to you
I have not considered selling, and given that the updates from the AVA6000 trials were positive, I am comfortable with my position, if not the SP. As long as the trials continue to deliver positive news, then I will average down as I am able (currently £1.39). Amazing potential here. Just feel for any who are forced to sell. Timing is everything. Wish I'd only just found out about Avacta now.
I'm in the same position; pushing my company towards Avacta as the first choice for LTFs. Medusa have told me that they cannot supply yet (at least they answered the call). Bioserve did not pick up the call I made to them, so I have filled out the online questionnaire, and am awaiting a response, as our company require tests for both employees and for business travel.
I agree; both NDN and Wyndrum's postings have become too ego-driven; posting for effect rather than contributing anything. Only my opinion, but it comes across as childish and takes up too much room on the forum. Neither of you are stupid, so why not reflect and just post when you have something of substance to say.
Just a quick in an out,; worked well for a change.
Thank you Mad for taking the time to post. I've been reading up on this, and have been aware of some shenigans, but am shocked how easy it would be to manipulate the market in this way. What's to stop a suitcase full of cash being shoved into a CEO's office to sweeten the deai?
In for a trade at 1.22. Surprisingly had to buy in small quantities, NT for £4k's worth. Just a quick trade hopefully.!
Interesting interview with @mlofgran of #NTOG on the company being offered money by MM's looking to close out an accumulated net short position.
This was re-tweeted by M Lofgran, which indicates he supports the interpretation.
I have read that a short position had to be closed, but it surely can't be closed this way. Anybody heard of such a thing before?